why choose us

First received: August 15, 2022

Clinical Trial: A Study to Evaluate the Efficacy and Safety of ALN-HSD in Adult Participants With Non-alcoholic Steatohepatitis (NASH) With Fibrosis With Genetic Risk Factors

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Nonalcoholic Steatohepatitis

Study Type: INTERVENTIONAL


Official Title: A Master Protocol of Randomized, Double-Blind, Placebo-Controlled, Phase 2 Studies of siRNA Gene Silencing for the Treatment of Non- Alcoholic Steatohepatitis (NASH) in Participants With Genetic Risk

Brief Summary: The study is researching an investigational drug called ALN-HSD (called "study drug" in this form).The study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH).NASH is a form of non-alcoholic fatty liver disease (NAFLD).NASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue).NASH can progress to cirrhosis (long term scarring) and liver failure (when your liver cannot perform its job).The aim of…

Read more